Back

Risk of stroke or systemic embolism according to baseline frequency and duration of subclinical atrial fibrillation: Insights from the ARTESiA trial

9 April 2024 (11:09 - 11:17)
Organised by: Logo
Congress Presentation Part of: Late-Breaking Science: devices Oral Anticoagulation EHRA Premium Access EHRA 2024 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Doctor William McIntyre

Population Health Research Institute, Hamilton (Canada)

9 More presentations in this session

Presentation thumbnail
Clinical benefits of the Closed Loop Stimulation in Sinus Node Disease
Doctor E. Pisano (Lecce, IT)
Slides Video
Presentation thumbnail
Clinical benefits of the Closed Loop Stimulation in Sinus Node Disease - discussion
Doctor N. Varma (Cleveland, US)
Slides Video
Presentation thumbnail
Effects of age, sex, cardiovascular comorbidities, and kidney function on outcomes with oral anticoagulation therapy in patients with device-detected atrial fibrillation. The NOAH-AFNET 6 trial.
Doctor J. Nikorowitsch (Hamburg, DE)
Slides Video
Presentation thumbnail
Effects of age, sex, cardiovascular comorbidities, and kidney function on outcomes with oral anticoagulation therapy in patients with device-detected atrial fibrillation. The NOAH-AFNET 6 trial. - discussion
Doctor S. Al-Khatib (Durham, US)
Slides Video
Presentation thumbnail
Risk of stroke or systemic embolism according to baseline frequency and duration of subclinical atrial fibrillation: Insights from the ARTESiA trial - discussion
Professor T. Potpara (Belgrade, RS)
Slides Video

Access the full session

Session thumbnail
Late-Breaking Science: devices
Video

The Event

Event poster

EHRA 2024

9 April 2024 11:09 CET
You may be interested in
thumbnail
Congress Presentation
Risk of stroke or systemic embolism according to baseline frequency and duration of subclinical atrial fibrillation: Insights from the ARTESiA trial - discussion
thumbnail
Congress Presentation
Subclinical and device-detected atrial fibrillation: risk of incident stroke
thumbnail
Congress Presentation
The Association between Age and Clinical Outcomes in Patients with Subclinical Atrial Fibrillation Treated with Apixaban: Insights from the ARTESiA Trial

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources